<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387059</url>
  </required_header>
  <id_info>
    <org_study_id>MS700623-0009</org_study_id>
    <nct_id>NCT03387059</nct_id>
  </id_info>
  <brief_title>Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle</brief_title>
  <acronym>ENDOMEDE</acronym>
  <official_title>A Multicentre, Prospective Randomised Controlled, Interventional Clinical Investigation to Assess the Clinical Safety and Performance of Forielle, a Medical Device for Endometrial Washing in Restoring Favorable Endometrial Condition to Implantation After COS During Assisted Reproductive Practice (ENDOMEDE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono S.P.A., Italy</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective randomized controlled, interventional investigation to
      assess the safety and clinical performance of Forielle, a medical device for endometrial
      washing, in restoring favorable endometrial condition to implantation after Controlled
      Ovarian Stimulation (COS) during Assisted Reproductive Technique (ART).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Implantation Rate</measure>
    <time_frame>Post Embryo Transfer (PET) Days 21 to 28</time_frame>
    <description>Subject implantation rate is defined as the number of intrauterine gestational sacs divided by the number of embryos transferred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive and Negative Pregnancy Result</measure>
    <time_frame>Post Embryo Transfer (PET) Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed Ongoing Pregnancy</measure>
    <time_frame>Post Embryo Transfer (PET) Days 70 to 84</time_frame>
    <description>Ongoing pregnancy will be confirmed via obstetric ultrasound (transvaginal or abdominal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Device Incidents</measure>
    <time_frame>Day 2 post-randomization (PR) up to Post Embryo Transfer (PET) Days 70 to 84</time_frame>
    <description>A medical device incident is any malfunction or deterioration in the characteristics and/or clinical performance of a device, as well as any inadequacy in the labelling or the instructions for use (IFU) which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2156</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Forielle Endometrial Washing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Endometrial Washing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Forielle</intervention_name>
    <description>Eligible subjects will be randomized to receive Forielle endometrial washing following oocyte retrieval on Study Day 0.</description>
    <arm_group_label>Forielle Endometrial Washing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All infertile women treated with intracytoplasmic sperm injection (ICSI)/Fertilization
             in Vitro and Embryo Transfer (FIVET)

          -  Less than or equal to (&lt;=) 1 previous failed embryo transfer

          -  Eumenorrheic normo-gonadotropic women

          -  Basal follicle-stimulating hormone (FSH) &lt;=12 International unit per liter (IU/L)

          -  Anti-mullerian hormone (AMH) greater than (&gt;) 1.1 nanogram per milliliter (ng/mL)

          -  Ovarian Reserve: number of antral follicles 2 millimeter (mm) between 6 &lt;= antral
             follicle count (AFC) &lt;= 16

          -  Follicles &gt; 16 mm at the triggering day between 5-14

          -  Body Mass Index (BMI) between 18 &lt;= BMI &lt;= 27 kilogram per meter square (kg/m^2)

          -  Indication for Fresh Embryo transfer

          -  Normal uterine cavity on ultrasound exam (e.g., no presence of hydrosalpinx)

          -  Undergoing Assisted Reproductive Technique (ART) and oocyte maturation by human
             chorionic gonadotropin (HCG) triggering

          -  Progesterone (P4) serum level at the HCG triggering day &lt;= 1.5 ng/mL (Day
             O/Randomization)

          -  Estradiol (E2) &lt;= 3000 picogram/milliliter (pg/mL) at the human chorionic gonadotropin
             (HCG) triggering day (Day 0/Randomization)

          -  Subjects must have read and signed the Informed Consent Form prior to
             study-specific-procedures not part of standard of care

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Clinically significant systemic disease (such as diabetes, metabolic syndrome,
             immunological diseases, diagnosed thrombophilia, porphyria, or any other medical
             condition requiring the use of low-molecular weight heparin therapy)

          -  Polycystic ovary syndrome (PCOS) according to Rotterdam Consensus Criteria (European
             Society of Human Reproduction and Embryology [ESHRE]/American Society for Reproductive
             Medicine [ASRM], 2003)

          -  Poor ovarian response (POR) according to the European Society of Human Reproduction
             and Embryology (ESHRE) Criteria

          -  RIF (repeated implantation failure), defined as greater than or equals to (&gt;=) 2
             previous failed embryo transfers

          -  Endometriosis III-IV stage or adenomyosis

          -  Clinically significant findings on exam or ultrasound, such as salpingitis,
             hydrosalpynx or evidence of ovarian cysts

          -  Known hypersensitivity to any of the components of the solution

          -  Known hypersensitivity to vaginal progesterone or its excipients

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.P.A., Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49-6151-72-5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <zip>64293</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Forielle</keyword>
  <keyword>Assisted Reproductive Technique (ART)</keyword>
  <keyword>Controlled Ovarian Stimulation (COS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

